Calithera Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALA research report →
Range $2 – $2
Price Chart
About the company
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business.
- CEO
- Stephanie Wong
- IPO
- 2014
- Employees
- 8
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on CALA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $487
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -131.13%
- ROIC
- -184.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-1,385,000-116.7%
- Op Income
- $-42,074,000
- Net Income
- $-18,866,000+83.6%
- EPS
- $-7.94+74.5%
- OCF Growth
- +34.2%
- FCF Growth
- +34.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.28
- RSI (14)
- 42
- Avg Volume
- 360
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Calithera said both mid-stage oncology readouts slipped to mid-2023 because of site activation delays, while cash of $34.1 million should fund operations only into Q2 2023 absent additional steps.· November 14, 2022
- Both Phase II programs are delayed; initial data for sapanisertib and mivavotinib is now expected in mid-2023 instead of Q1.
- Management blamed the slower start on site activation delays and post-pandemic staffing shortages, not on drug issues.
- Cash and cash equivalents were $34.1 million at September 30, 2022, with runway expected into the second quarter of 2023.
- The company is actively exploring strategic collaborations, licensing, and possible asset sales to extend runway.
- Sapanisertib received FDA Fast Track designation, which management says could help with more frequent FDA dialogue and a rolling submission path.
Cash and cash equivalents were $34.1 million at September 30, 2022, and management said this should fund the current operating plan into the second quarter of 2023. Third-quarter 2022 R&D expense was $6.5 million versus $11.6 million a year ago, reflecting lower telaglenastat, CB-280 and early-stage research spend partly offset by higher sapanisertib and mivavotinib costs. Third-quarter 2022 G&A expense was $3.0 million versus $6.3 million last year, mainly due to lower personnel-related and legal costs. Net loss for the three months ended September 30, 2022 was $9.8 million. Forward, initial clinical data for both sapanisertib and mivavotinib is now expected in mid-2023, and the company is evaluating strategic collaborations, licensing, and possible program sales to extend cash runway.
Susan Molineaux emphasized that Calithera still believes in the potential of sapanisertib and mivavotinib, but the company is dealing with operational delays at clinical sites. She said the team expects investigators to begin enrolling once sites are open and that the readout delay is primarily a timing issue, not a change in conviction about the programs. She also stressed that Fast Track for sapanisertib could be important for ongoing FDA interaction and a possible path to registration.
Stephanie Wong said the quarter ended with $34.1 million in cash and cash equivalents, which she expects to support operations into Q2 2023 under the current plan. She highlighted lower operating expenses year over year: R&D fell to $6.5 million from $11.6 million, and G&A fell to $3.0 million from $6.3 million, with the R&D decline tied mainly to telaglenastat, CB-280, and early-stage research reductions. She also said the company is considering all options across its programs to extend runway, but did not disclose scenario details.
Analysts pressed on why enrollment delays were only becoming clear now, and management said the issues emerged unexpectedly at different sites, largely due to staffing shortages and other site-specific problems that became more visible in the last quarter. Management said the sites are opening now, and enrollment should steepen as they come online. Questions also focused on whether Calithera would need initial Phase II data to secure partnerships or extend runway; Susan Molineaux said it does not need to wait for those readouts to pursue runway-extending actions. On potential asset sales, sublicensing, or pausing a trial, management would not specify transaction structures but confirmed those options are under consideration.
Management reiterated confidence that both drugs have already shown single-agent activity in the relevant populations, and said the current studies are mainly about confirming that signal and refining dose. Fast Track for sapanisertib gives Calithera more frequent FDA engagement and possible rolling review, which could help if the data are supportive. The company also has multiple levers to extend runway before the mid-2023 data window.
The biggest risk is financing: with $34.1 million in cash, management expects funding only into Q2 2023 unless it can strike a partnership, license, sale, or other capital-preserving move. Both clinical readouts slipped from Q1 to mid-2023 because site activation delays and staffing issues slowed enrollment, showing execution risk in both programs. Management would not rule out pausing a trial or selling assets, which underscores pressure to conserve cash.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 4.87M
- Float Shares
- 4.83M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Delphi Management Partners Viii, L.L.C. | 2.43M | 0 |
| Marshall Wace North America L.P. | 307.24K | ▲ 307.24K |
| Qs Investors, LLC | 133.20K | ▲ 133.20K |
| Aperio Group, LLC | 15.53K | ▲ 15.53K |
| Xtx Markets LLC | 10.14K | ▲ 10.14K |
Held by 1 ETFs
Biggest fund positions in CALA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 23 | TAKEDA PHARMACEUTICAL CO LTD | other | 1,000,000 |
| Jan 27, 23 | PAKIANATHAN DEEPIKA | sell | 1,172 |
| Jan 23, 23 | Sjogren Eric | other | 279 |
| Jan 23, 23 | Kuriakose Emil | other | 79 |
| Jan 23, 23 | Molineaux Susan | other | 526 |
| Jan 23, 23 | Wong Stephanie | other | 317 |
| Jan 23, 23 | Molineaux Christopher | other | 217 |
| Jul 1, 22 | Takeda Ventures, Inc. | other | 1,000,000 |
| Jul 1, 22 | TAKEDA PHARMACEUTICAL CO LTD | other | 1,000,000 |
| Jul 1, 22 | TAKEDA PHARMACEUTICAL CO LTD | other | 1,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CALA coverage
Recent articles, reports, and earnings notes.
No research on CALA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CALA report →Calithera Biosciences (NASDAQ:CALA) Shares Break Above 50 Day Moving Average – What’s Next?
defenseworld.net · Oct 10
Vistance Networks Reports Second Quarter 2026 Results
gurufocus.com · Aug 6
Calithera Biosciences (NASDAQ:CALA) Shares Pass Above Fifty Day Moving Average – What’s Next?
defenseworld.net · Mar 31
Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast
defenseworld.net · Mar 9
Calithera Biosciences (NASDAQ:CALA) Stock Passes Above Fifty Day Moving Average – Time to Sell?
defenseworld.net · Jan 10
Marriott International Announces Changes to its Continent Leadership and a Strategic Realignment Across Key Regions
prnewswire.com · Jan 9
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
seekingalpha.com · Nov 14
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
globenewswire.com · Nov 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.